Poster Session 4
Category: Diabetes
Poster Session 4
Paola A. Lopez-Zapana, PhD
Postdoctoral Researcher, Massachusetts General Hospital
Vincent Center for Reproductive Biology, Massachusetts General Hospital
Boston, Massachusetts, United States
Rachelly Normand, PhD
Postdoctoral Researcher, Massachusetts General Hospital
Krantz Family Center for Cancer Research, Massachusetts General Hospital; Harvard Medical School
Boston, Massachusetts, United States
Daehee Han, PhD
Research Scientist
Vincent Center for Reproductive Biology, Massachusetts General Hospital; Department of Obstetrics and Gynecology, MassGeneral Brigham; Division of Maternal-Fetal Medicine; Harvard Medical School
Boston, Massachusetts, United States
Olyvia J. Jasset, BA
Vincent Center for Reproductive Biology, Massachusetts General Hospital
Boston, Massachusetts, United States
Laura Ibanez-Pintor, MD (she/her/hers)
Postdoctoral Research Fellow
Vincent Center for Reproductive Biology, Massachusetts General Hospital
Boston, Massachusetts, United States
Douglas A. Lauffenburger, PhD
Department of Biological Engineering, Massachusetts Institute of Technology
Cambridge, Massachusetts, United States
Alexandra-Chloé Villani, PhD
Center for Immunology and Inflammatory Diseases, Krantz Family Center for Cancer Research, Massachusetts General Hospital
Boston, Massachusetts, United States
Andrea G. Edlow, MD, MSc (she/her/hers)
Associate Professor
Department of Obstetrics and Gynecology, MassGeneral Brigham; Division of Maternal-Fetal Medicine; Harvard Medical School
Boston, Massachusetts, United States
Lydia L. Shook, MD (she/her/hers)
Assistant Professor
Department of Obstetrics and Gynecology, MassGeneral Brigham; Division of Maternal-Fetal Medicine; Harvard Medical School
Massachusetts General Hospital/Boston, Massachusetts, United States
Individuals with type 1 diabetes (T1D), an autoimmune disorder with insulin deficiency and metabolic dysregulation, have increased risk of placental dysfunction and adverse pregnancy outcomes. The molecular mechanisms underlying pregnancy morbidity in T1D are poorly understood. We examined placental gene programs at the single-cell level in T1D pregnancies.
Study Design:
We collected 19 placental samples from T1D pregnancies (N=10) and healthy controls (N=9), balanced for fetal sex. We profiled maternal and fetal cells using 10x Genomics single-cell RNA sequencing. Genetic demultiplexing determined maternal/fetal cell origin. Differentially expressed genes (DEGs) between T1D and controls were identified across cell subclusters (threshold: fold change >1.5, FDR < 0.1). Pathway analysis (Ingenuity) was performed on subclusters with ≥50 DEGs.
Results:
Of 114 trophoblast, immune, and stromal subpopulations identified, 35 were dysregulated by T1D (Fig. 1). Villous cytotrophoblasts (VCTs), maternal CD14+ monocytes, fetal S100A8+ macrophages (Hofbauer subset), and fetal endothelial cells were most impacted. Dysregulated canonical pathways included upregulated oxidative phosphorylation and mitochondrial function in VCTs, altered activation patterns in macrophages, and dysregulated IL-4/13 and JAK-mediated cytokine signaling in fetal endothelial cells, indicating fetal inflammation (Fig. 2A). Multiple disease functions were upregulated in fetal endothelial cell subtypes: cell survival, leukocyte adhesion/migration, and angiogenesis (Fig. 2B). Glucose metabolism disorder pathways were upregulated in maternal and fetal macrophage subtypes.
Conclusion:
Examination of the maternal-fetal interface at the single-cell level revealed novel immune and metabolic gene pathways impacted by T1D. These findings suggest an impact of maternal T1D across the maternal-fetal interface that may have implications for offspring cardiometabolic programming.